Published in Vaccine Weekly, November 29th, 1999
The immune-based investigational therapy appeared safe and well tolerated, and a statistically significant (P< 0.05) percentage of patients with improvement in their disease condition was observed after the third injection of IR501 Therapeutic Vaccine using the ACR 20 criteria for improvement. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly